184 related articles for article (PubMed ID: 35561484)
1. 'Red Flags' and 'Red Tape': Telehealth and pharmacy-level barriers to buprenorphine in the United States.
Textor L; Ventricelli D; Aronowitz SV
Int J Drug Policy; 2022 Jul; 105():103703. PubMed ID: 35561484
[TBL] [Abstract][Full Text] [Related]
2. Addressing buprenorphine bottlenecks in the context of MAT Act implementation: A shared responsibility.
Ostrach B; Hill L; Carpenter D; Pollini R
J Am Pharm Assoc (2003); 2023; 63(4):1044-1048. PubMed ID: 37149144
[TBL] [Abstract][Full Text] [Related]
3. Telehealth for opioid use disorder treatment in low-barrier clinic settings: an exploration of clinician and staff perspectives.
Aronowitz SV; Engel-Rebitzer E; Dolan A; Oyekanmi K; Mandell D; Meisel Z; South E; Lowenstein M
Harm Reduct J; 2021 Nov; 18(1):119. PubMed ID: 34823538
[TBL] [Abstract][Full Text] [Related]
4. Buprenorphine implementation at syringe service programs following waiver of the Ryan Haight Act in the United States.
Lambdin BH; Bluthenthal RN; Tookes HE; Wenger L; Morris T; LaKosky P; Kral AH
Drug Alcohol Depend; 2022 Aug; 237():109504. PubMed ID: 35688052
[TBL] [Abstract][Full Text] [Related]
5. The impact of the mainstreaming addiction treatment act and associated legislative action on pharmacy practice.
Varisco TJ; Wanat M; Hill LG; Thornton D
J Am Pharm Assoc (2003); 2023; 63(4):1039-1043. PubMed ID: 37088366
[TBL] [Abstract][Full Text] [Related]
6. Use of and Retention on Video, Telephone, and In-Person Buprenorphine Treatment for Opioid Use Disorder During the COVID-19 Pandemic.
Frost MC; Zhang L; Kim HM; Lin LA
JAMA Netw Open; 2022 Oct; 5(10):e2236298. PubMed ID: 36223118
[TBL] [Abstract][Full Text] [Related]
7. Perceptions, policies, and practices related to dispensing buprenorphine for opioid use disorder: A national survey of community-based pharmacists.
Hill LG; Light AE; Green TC; Burns AL; Sanaty Zadeh P; Freeman PR
J Am Pharm Assoc (2003); 2023; 63(1):252-260.e6. PubMed ID: 36202711
[TBL] [Abstract][Full Text] [Related]
8. COVID-19: A catalyst for change in telehealth service delivery for opioid use disorder management.
Mehtani NJ; Ristau JT; Snyder H; Surlyn C; Eveland J; Smith-Bernardin S; Knight KR
Subst Abus; 2021; 42(2):205-212. PubMed ID: 33684331
[TBL] [Abstract][Full Text] [Related]
9. Ensuring buprenorphine access in rural community pharmacies to prevent overdoses.
Ostrach B; Potter R; Wilson CG; Carpenter D
J Am Pharm Assoc (2003); 2022; 62(2):588-597.e2. PubMed ID: 34674965
[TBL] [Abstract][Full Text] [Related]
10. Barriers to Buprenorphine Dispensing by Medicaid-Participating Community Retail Pharmacies.
Freeman PR; Hammerslag LR; Ahrens KA; Sharbaugh M; Gordon AJ; Austin AE; Donohue JM; Allen LD; Barnes AJ; Talbert JC
JAMA Health Forum; 2024 May; 5(5):e241077. PubMed ID: 38758569
[TBL] [Abstract][Full Text] [Related]
11. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
[TBL] [Abstract][Full Text] [Related]
12. Buprenorphine prescribing and treatment accessibility in response to regulation changes due to the COVID-19 public health emergency.
Paiva TJ; Wightman RS; St John K; Nitenson AZ; Onyejekwe C; Hallowell BD
J Subst Use Addict Treat; 2024 Jul; 162():209382. PubMed ID: 38677597
[TBL] [Abstract][Full Text] [Related]
13. Telehealth Initiation of Buprenorphine for Opioid Use Disorder: Patient Characteristics and Outcomes.
Nguyen B; Zhao C; Bailly E; Chi W
J Gen Intern Med; 2024 Jan; 39(1):95-102. PubMed ID: 37670069
[TBL] [Abstract][Full Text] [Related]
14. Medication treatment for opioid use disorder in the age of COVID-19: Can new regulations modify the opioid cascade?
Nunes EV; Levin FR; Reilly MP; El-Bassel N
J Subst Abuse Treat; 2021 Mar; 122():108196. PubMed ID: 33221125
[TBL] [Abstract][Full Text] [Related]
15. Using telehealth to improve buprenorphine access during and after COVID-19: A rapid response initiative in Rhode Island.
Clark SA; Davis C; Wightman RS; Wunsch C; Keeler LAJ; Reddy N; Samuels EA
J Subst Abuse Treat; 2021 May; 124():108283. PubMed ID: 33771282
[TBL] [Abstract][Full Text] [Related]
16. Impact of COVID-19 Telehealth Policy Changes on Buprenorphine Treatment for Opioid Use Disorder.
Lin LA; Zhang L; Kim HM; Frost MC
Am J Psychiatry; 2022 Oct; 179(10):740-747. PubMed ID: 35899380
[TBL] [Abstract][Full Text] [Related]
17. The COVID-19 pandemic and opioid use disorder: Expanding treatment with buprenorphine, and combining safety precautions with telehealth.
Cales RH; Cales SC; Shreffler J; Huecker MR
J Subst Abuse Treat; 2022 Feb; 133():108543. PubMed ID: 34210567
[TBL] [Abstract][Full Text] [Related]
18. Improving equity and access to buprenorphine treatment through telemedicine at syringe services programs.
Lambdin BH; Kan D; Kral AH
Subst Abuse Treat Prev Policy; 2022 Jul; 17(1):51. PubMed ID: 35841036
[TBL] [Abstract][Full Text] [Related]
19. Characteristics and correlates of U.S. clinicians prescribing buprenorphine for opioid use disorder treatment using expanded authorities during the COVID-19 pandemic.
Jones CM; Diallo MM; Vythilingam M; Schier JG; Eisenstat M; Compton WM
Drug Alcohol Depend; 2021 Aug; 225():108783. PubMed ID: 34049102
[TBL] [Abstract][Full Text] [Related]
20. Buprenorphine physician-pharmacist collaboration in the management of patients with opioid use disorder: results from a multisite study of the National Drug Abuse Treatment Clinical Trials Network.
Wu LT; John WS; Ghitza UE; Wahle A; Matthews AG; Lewis M; Hart B; Hubbard Z; Bowlby LA; Greenblatt LH; Mannelli P;
Addiction; 2021 Jul; 116(7):1805-1816. PubMed ID: 33428284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
